Product Name | Doxorubicin Hydrochloride |
Description |
Apoptosis inducer |
Purity | >98% (TLC); NMR (Conforms) |
CAS No. | 25316-40-9 |
Molecular Formula | C27H29NO11•HCl |
Molecular Weight | 580 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inducer |
Solubility | May be dissolved in water (25 mg/ml); or DMSO (30 mg/ml). |
Source | Synthetic |
Appearance | Red- Orange Powder |
SMILES | [C@H]2(OC1OC(C(O)C(N)C1)C)C[C@@](O)(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)C(=O)CO.[H+].[Cl-] |
InChI | InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3 |
InChIKey | MWWSFMDVAYGXBV-RUELKSSGSA-N |
Safety Phrases |
Classification: Not WHMIS controlled. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H302- Harmful if swallowed. H350- May cause cancer. Precautionary statements: P201- Obtain special instructions before use. P308 + P313- IF exposed or concerned: Get medical advice/ attention. |
Cite This Product | Doxorubicin Hydrochloride (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-390) |
Alternative Names | Adriamycin |
Research Areas | Alzheimer's Disease, Apoptosis, Cancer, Cell Signaling, DNA Synthesis, DNA/RNA, Epigenetics and Nuclear Signaling, Neurodegeneration, Neuroscience, Topoisomerases |
PubChem ID | 443939 |
Scientific Background | Doxorubicin Hydrochloride is used in a clinical setting for the treatment of a wide range of cancers, including lymphomas, leukemias, and solid tumors of the breast, pancreas, stomach, bladder, and ovaries. This drug intercalates into DNA and therefore induces apoptosis by hindering cellular functions like replication and transcription by specifically inhibiting the binding of reverse transcriptase, RNA polymerase and topoisomerase II. Doxorubicin has some adverse effects for patients including immunosuppressive effects caused by hematologic toxicity. Doxorubicin has also been shown to induce autophagy in a species-specific manner. |
References |
1. Kusayanagi, T. et al. (2012). Bioorg Med Chem. 20(21): 6248-55. 2. Chen, N. T. et al. (2012). PLoS One. 7(9). 3. Patel, S. et al. (1997). Mol Pharmacol. 52(4): 658-66. 4. Cutts, S. et al. (1996). J Biol Chem. 271(10): 5422-9. 5. Danesi, R. et al. (2004). Transplant Proc. 36(3): 703-4. 6. Dirks-Naylor, A. (2013). Life Sci. 93(24): 913-6. |
Reviews
There are no reviews yet.